8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 3, 2007

SCIELE PHARMA, INC.
(Exact name of registrant as specified in charter)

Delaware	000-30123	58-2004779
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Five Concourse Parkway
Suite 1800
Atlanta, Georgia 30328
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (770) 442-9707

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Item 8.01               Other Events

On August 3, 2007, Sciele Pharma, Inc. (the “Company”) announced that its Board of Directors has adopted a new share repurchase program, effective August 3, 2007, authorizing the repurchase of up to $40 million of its outstanding shares of common stock over the next twelve months.  The Company’s previous $30 million repurchase program expired on August 2, 2007, at which time approximately $8 million remained in authorized but unexecuted repurchases at termination.  Such unexecuted repurchases have expired.  A copy of the press release is attached to this Report as Exhibit 99.1

Item 9.01               Financial Statements and Exhibits

99.1         Press release dated August 3, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SCIELE PHARMA, INC.
	(Registrant)
By:	/s/ Darrell Borne
Name:	Darrell Borne
Title:	EVP, Chief Financial Officer, Secretary and Treasurer

Date:  August 7, 2007

2

EX-99.1

Exhibit 99.1

SCIELE PHARMA, INC. ADOPTS
$40 MILLION SHARE REPURCHASE PROGRAM

ATLANTA (August 3, 2007) — Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that its Board of Directors has adopted a new share repurchase program, authorizing the repurchase of up to $40 million of its outstanding shares of common stock over the next twelve months.  The plan became effective on August 3, 2007.

Sciele Pharma may conduct its purchases in the general market and in privately negotiated transactions.  The repurchase program does not require Sciele Pharma to acquire any specific number of shares and may be terminated at any time.  The Company’s previous $30 million repurchase program expired on August 2, 2007, at which time approximately $8 million remained in authorized but unexecuted repurchases at termination.  Such unexecuted repurchases have expired.

Sciele Pharma, Inc. Background

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes, Women’s Health and Pediatrics. The Company’s Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women’s Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, coughs and colds, and attention deficit/hyperactivity disorder (ADHD). Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 900 people. The Company’s success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform — an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity, and Teamwork.

CONTACT: Sciele Pharma, Inc.
Joseph T. Schepers, 678-341-1401
ir@sciele.com